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ABSTRACT
Rowell syndrome is a rare skin disease described as an association of erythema multiforme and system-
ic lupus erythematosus, immunologically characterized by speckled antinuclear, anti-Ro, and anti-La 
antibodies. The majority of described cases affect middle-aged women. We report a case of a 53-year-old 
man with no previous history of lupus erythematosus, who developed erythema multiforme-like lesions and 
immunological findings consistent with Rowell syndome upon an intake of non-steroidal anti-inflammato-
ry drugs. The patient responded well to systemic steroids and hydroxychloroquine. A short overview, empha-
sizing the specific clinical, laboratory and histology findings of this peculiar syndrome, is also presented.
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INTRODUCTION
Scholtz first described the association between 
lupus erythematosus (LE) and erythema multiforme 
(EM) in 1922 (1). In 1963 Rowell et al. reported a rare 
distinctive entity, characterized by discoid lupus and 
EM-like lesions, positive rheumatoid factor, speckled 
antinuclear antibody, and precipitating antibody to 
saline extract of human tissue (2). In 2000, Zeitouni 
and coworkers suggested major (coexistence of LE, 
EM-like lesions and speckled ANA pattern) and 
minor (chillblains, positive RF, and anti-Ro or anti-
La antibodies) diagnostic criteria (3). Up to date, only 
12 male patients with Rowell syndrome have been 
reported worldwide (4,5). 
Herein, we report a case of drug-induced Rowell 
syndrome in a male patient.
CASE REPORT
A 53-year-old Caucasian man was admitted 
to our Department with a 2-month history of pain-
ful blisters and erosions on photo-exposed areas to-
gether with extended oral ulcerations. The skin le-
sions appeared upon a common cold treated with an-
ti-inflammatory drugs – ibuprofen, paracetamol and 
metamizol. He had no previous medical history. No 
concomitant medications were taken. 
Skin examination revealed significant erythe-
ma, edema, annular target-like lesions with blister 
formation and central necrosis, symmetrically dis-
turbed on the sun-exposed areas (Fig. 1). Multiple 
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Autoimmune screening showed highly elevated 
ANA (1:1280), increased levels of anti-ds DNA (>200) 
and positive levels of anti-Ro (anti-SSA) and anti-La 
(anti-SSB) antibodies. The complement fragments 
were decreased (C3 – 61 mg/dL and C4 - 20 mg/dL). 
The rheumatoid factor was negative.  
Nail fold capillaroscopy revealed spastic cramp 
in the microcirculation of both hands. The chest X-
ray, electrocardiogram and abdominal ultrasound 
were normal.
Based on the clinical, histopathological, labo-
ratory and immunological findings, the diagnosis of 
drug-induced Rowell syndrome was established. In-
travenous methylprednisolone (80 mg per day), oral 
chloroquine phosphate (500 mg per day) and topical 
clobetasol propionate ointment were initiated with 
fast improvement, which allowed the discontinua-
tion of corticosteroids in one month. At that point 
the skin lesions showed complete resolution with 
mild residual poikiloderma (Fig. 3). The patient was 
maintained on low-dose oral choroquine phosphate 
for 6 months. No recurrence occurred during this 
follow-up period.
DISCUSSION
Rowell syndrome is a rare presentation of lupus 
erythematosus with erythema multiforme-like le-
sions.  Most of the cases have been described in mid-
dle-aged women (6). We have described a 53-year-old 
male.
small ulcers over extended enanthema were seen on 
hard palate and buccal mucosa. Skin biopsy revealed 
necrotic epidermis, vacuolar degeneration of the bas-
al keratinocytic layer, and obscured dermo-epider-
mal junction by dense mixed inflammatory infiltrate 
intermingled with few eosinophils (Fig. 2). The di-
rect immunofluorescence from an erythema multi-
forme-like lesion was negative.
Laboratory studies showed anemia (Hb-109g/L), 
increased erythrocyte sedimentation rate (87 mm/h), 
elevated C-reactive protein test (7.7 mg/L) and elevat-
ed functional liver tests (ASAT 98.3 U/L; ALAT 51.5 
U/L; GGT-87.0 U/L). 
Fig. 1. Targetoid erythematous lesions with superficial 
blisters covered with hemorrhagic crusts on the trunk of 
the patient
Fig. 2. Necrotic epidermis, vacuolar degeneration of the 
basal keratinocytic layer, mild interstitial and perivascu-
lar lympho-plasmocytic infiltration in the papillary der-
mis. Histological changes consistent with erythema multi-
forme (HE, x 200)
Fig. 3. Postlesional poikilodermic changes upon 1 month 
of therapy with corticosteroids and antimalarial drugs
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A great controversy exists on the exact taxono-
my of Rowell syndrome. Due to inconsistent features 
the diagnostic criteria have been changed during the 
years.  Rowell et al. coined the initial paradigms: er-
ythema multiforme-like lesions, speckled pattern of 
ANA, rheumatoid factor, and positive saline extract 
of human tissue (anti-SJT - now regarded as similar 
to anti-Ro) (2). Chilblains were included in 1995 (7). 
In 2000, Zeitouni et al. suggested major (SLE, DLE, 
or subacute cutaneous LE, EM-like lesions with or 
without mucosal involvement, and speckled pat-
tern of ANA) and minor (chilblains, anti-Ro/anti-
La antibody, and a positive RF) diagnostic criteria. 
All three major criteria and at least one minor crite-
rion are needed to verify the disease (3). Total anti-
nuclear antibody positivity is the most consistent fea-
ture of Rowell syndrome. It is registered in more than 
80% of the patients. Hence, rheumatoid factor is pos-
itive in only 41% of the cases (8,9).  Our case meets 
all Zeitouni’s major and most minor criteria with the 
exception of positive rheumatoid factor. 
The most recent Rowell syndrome diagnostic 
criteria were proposed by Torchia et al. in 2012 (10). 
The diagnosis requires 4 major and one minor cri-
teria. The major criteria are: (1) presence of chronic 
CLE (DLE and/or chilblain); (2) presence of EM-like 
lesions (typical or atypical targets); (3) at least 1 posi-
tivity among speckled ANA, anti-Ro/SS-A, and anti-
La/SS-B antibodies, and (4) negative DIF on lesional 
EM-like targetoid lesions. The minor criteria include: 
(1) lack of infectious or pharmacologic triggers; (2) 
absence of typical EM location (acral and mucosal), 
and (3) presence of at least 1 additional American 
College of Rheumatology criterion for diagnosis of 
SLE besides discoid rash and positive ANA antibod-
ies and excluding photosensitivity, malar rash, and 
oral ulcers. Our diagnosis is completely compatible 
with these diagnostic features. 
Rowell syndrome has been described with all 
subtypes of LE (systemic, acute, subacute or discoid) 
(2, 3, 11). Our patient shows characteristics of acute 
systemic lupus erythematosus, verified by the pres-
ence of oral ulceration, anemia, ANA positivity with 
speckled pattern, increased levels of anti-dsDNA an-
tibody and decreased complement levels.
Erythema multiforme is usually triggered by in-
fectious agents, mainly Mycoplasma pneumonia and 
herpes simplex virus, malignancies or drugs such as 
antibiotics, tuberculostatics, anti-convulsants, and 
nonsteroid anti-inflammatory medications (12). In 
our case, the patient had a history of common cold 
preceding the onset of skin lesions. Therefore, he had 
taken a cocktail of anti-inflammatory drugs and an-
tipyretics (ibuprofen, paracetamol and metamizol), 
thus raising the suspicion of possible drug induction. 
SLE and Rowell syndrome respond to a simi-
lar treatment. Antimalarials, steroids, azathioprine, 
dapsone, and cyclosporine have been used with sat-
isfactory results (13-16). Our patient had an excellent 
response on combined corticosteroid and antimalar-
ial regimen with complete resolution of skin lesions 
within a month.
CONCLUSION
Despite its rarity, Rowell syndrome should be 
suspected in any patient that shows EM lesions in as-
sociation with LE immunological features. Drug in-
duction in genetically predisposed patients is also 
possible. 
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